Today, the pharmaceutical sector continued to strengthen, with the Hang Seng Biotech Index (HSBIO.HI) rising 3.21% during the session. In terms of related ETFs, the Hong Kong Stock Connect Biotech ETF (159102) is currently up 2.91%. As of the data from the last trading day, this fund has accumulated a rise of 8.26% over the past 15 days, showing strong momentum. Among the constituent stocks, 3SBio rose over 6%, AKESO rose over 4%, Innovent Biologics rose over 3%, and companies like Yinxin Biologics-B, Kelun-Biotech-B, and Crystal Clear Holdings also saw significant gains. Meanwhile, the Biomedicine ETF (159508) is currently up 0.61%, and the Healthcare ETF (512120) is currently up 1.08%.
On the news front, the outbound innovation drug market continues to thrive. Data from the National Medical Products Administration shows that in the first quarter of 2026, the number of outbound licensing (BD) transactions for China's innovative drugs reached 53, with upfront payments exceeding USD 3.3 billion and total transaction amounts surpassing USD 60 billion, approaching half of the total for the entire year of 2025. Domestic innovative drugs have shifted from sporadic outbound activities to a systematic trend, with their global share continuously rising. From the beginning of the year to now, the number of domestic innovative drug BD projects and the disclosed amounts account for 20% and 75% of the global total, respectively.
Huayuan Securities stated that the valuation of the innovative drug sector remains low, and with medical conferences such as AACR and ASCO approaching, a new round of market activity is expected. They suggest focusing on the IO2.0 and ADC fields, as well as targets with substantial clinical progress and BD expectations. Additionally, the CXO industry chain and cross-border medical enterprises, which are expected to perform well in Q1, are also worth paying attention to.
Kaiyuan Securities indicated that the pharmaceutical industry continues to focus on the innovative drug industry chain and related strategic emerging industries, including CXO, research services, AI, and brain-computer interfaces.
Daily Economic News

09926

159316

The overseas expansion of innovative drugs continues to thrive, with the transaction value of China's innovative drug licensing exceeding USD 60 billion in the first quarter of 2026. The pharmaceutical sector performed strongly, with the Hang Seng Biotech Index rising by 3.21%. Related ETFs also saw significant increases, with notable gains in constituent stocks such as Sanofi and AKESO. Huayuan Securities and Kaiyuan Securities are both optimistic about the long-term development potential of the innovative drug industry chain and related emerging industries, suggesting attention to investment opportunities in these areas

腾讯新闻 - 财经

AKESO

E Fund Hang Seng SCHK Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

CAM HSBIOTECH

Huaan Hang Seng Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CSI Biotechnology Theme Index Initiating Fund(LOF)-A

China Merchants CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Guotai Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

3SBIO

INNOVENT BIO

DUALITYBIO-B

SKB BIO

JIANGSU HORIZON

Huaan CNI Biomedicine ETF

Huaan CSI Subdivision Medicine ETF

Sunshine Guojian Pharmaceutical

The explosion of innovative drugs going overseas! In the first quarter, the BD transaction amount exceeded 60 billion USD